With the increasing number of biologics and immune-targeting drugs in discovery and development, and their inherent risk of triggering adverse drug reactions in patients, being able to predict and measure potential immunotoxicological consequences is more important than ever.
The assessment of cytokine release assays (CRAs) plays a key role in developing immunomodulatory therapeutics. Our experts for this panel discussion share their knowledge on the following topics:
- The background and development of CRAs
- Regulatory expectations
- Examining translatability data
- Case studies on the mechanisms of cytokine release
David Eastwood, PhD
Client Services Manager
Keith Sutton PhD
Danice Wilkins, PhD, MS
Scientific Director, Immunology & Biomarkers
Marie-Soleil Piche, PhD
Scientific Director Immunology
We are providing digital education options to keep you learning about topics you may be interested in. For more information, visit criver.com/digital-education.